Features
23 It’s time for an end to pharma exceptionalism
26 January 2026Features
26 The ‘jagged frontier’, straight talk and why humans still matter
Picking your omnichannel direction requires a disciplined, scientific approach
26 January 2026Features
25 GenAI in healthcare – friend or foe?
26 January 2026Features
18-19 Patient-centricity in rare disease: accelerating the path to treatment
CAR-Ts pose a unique challenge for healthcare systems, exacerbated by uncertainty around their long-term, real-world value
26 January 2026Features
16-17 The world’s most studied diseases: four lessons from 2025
Across almost every sector, brands are multiplying their investment in creativity
26 January 2026Features
15 HEALTHCARE: WHEN PATIENTS ASK AI FIRST: WHAT EMERGING AI HEALTH FEATURES MEAN FOR PHARMA
26 January 2026Features
14 MAXINE SMITH AND SIMON CAMPLING
26 January 2026Features
15 HEALTHCARE: How personalised healthcare will shape pharma’s role and reputation by 2030
26 January 2026Features
14 GORDON DANIELS PUTTING AI TO WORK FOR PHARMA MARKETING LEADERS OF THE FUTURE
26 January 2026Features
27 Connecting through the chaos – why medical affairs needs creative problem-solving
26 January 2026Features
24-26 ASH 2025
Picking your omnichannel direction requires a disciplined, scientific approach
26 January 2026Features
22-23 Oral health and systemic disease: why they may be more closely linked than we thought
26 January 2026Features
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services